Recommendation of the President – Agamree (vamorolone) in the indication of Becker muscular dystrophy

On 24 July 2024 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation No. 74/2024 on the appropriateness of issuing approvals for the reimbursement of a medicinal product Agamree (vamorolone) in the indication of Becker muscular dystrophy

Publication in Public Information Bulletin (BIP) >>